Executive Summary
Long-term randomized data now show TAVR and SAVR deliver equivalent cardiovascular mortality and stroke through 3-10 years in low-risk patients, but the pacemaker penalty persists and the reintervention signal concentrates in self-expanding platforms — a meta-analysis of four RCTs (N=3,014) that tightens the platform-specific case rather than the transcatheter-versus-surgery case. VA data show diagnosis-to-TAVR delays over 90 days nearly triple mortality (HR 2.98), exposing system-level failure as a larger threat than any device-level debate. A Medicare analysis of sequential transcatheter valve interventions quantifies for the first time how often patients return for a second valve — 4.48% after TMVR by five years — reframing "one-and-done" marketing.
- Ten-year NOTION data embedded in the meta-analysis show less severe SVD with self-expanding TAVR than SAVR, but excess reintervention with the same platform (J Thromb Thrombolysis).
- Early oral anticoagulation within 2 days after TAVR in AF cut 1-year NACE by 16% versus days 5-7 initiation in 6,744 propensity-matched patients (TriNetX cohort).
- Hybrid suture-plus-plug vascular closure halved major vascular complications versus dual-suture in transfemoral TAVR across 2,308 patients (JSCAI meta-analysis).
- ViV-TAVR dominates redo-SAVR economically at $88,829 vs $91,411 with marginally better 2-month survival, though only in 57-58% of simulations (JSCAI decision model).
- The EDGEFIRM trial launches to test M-TEER + GDMT versus GDMT alone in HFpEF patients with atrial functional MR — the population COAPT and RESHAPE-HF2 excluded.
What to watch: Boston Scientific reports July 29 earnings, the first read on Watchman and structural heart volumes after the stock's 53% six-month collapse.
Aortic Valve (TAVR/TAVI)
Platform matters more than modality. The latest low-risk meta-analysis (4 RCTs, N=3,014, up to 10-year follow-up) finds no difference in cardiovascular mortality (HR 1.11) or stroke (HR 1.09) between TAVR and SAVR, but pacemaker implantation runs 2.08-fold higher with TAVR overall — and 2.57-fold with self-expanding valves versus 1.40-fold with balloon-expandable (p=0.02 for interaction). Reintervention excess also concentrated in the self-expanding arm. The 10-year NOTION signal of less severe SVD with TAVR is real but derives from one trial and one platform; generalizing it to low-risk 60-year-olds is a leap the data does not yet support. ACC/AHA 2020 still favors SAVR under 65, and ESC 2025 raised the SAVR-preferred ceiling to under 70 precisely because RCT representation thins below that age. [NOTABLE] VA outpatients waiting over 90 days from diagnosis to TAVR had a mortality HR of 2.98 — a system failure that dwarfs the platform debate. Hybrid suture-plus-plug closure cut major vascular complications by half (RR 0.50) across six studies, and early OAC within 2 days post-TAVR in AF patients reduced 1-year NACE (HR 0.79) without a bleeding penalty.
Mitral Valve (MitraClip, PASCAL, TMVR)
Atrial functional MR finally gets a randomized trial. EDGEFIRM will randomize symptomatic HFpEF patients with aFMR 2:1 to M-TEER + GDMT versus GDMT alone — the exact cohort COAPT, MITRA-FR, and RESHAPE-HF2 excluded. ESC 2025 already recognizes atrial SMR as a distinct entity and gives TEER a Class IIb nod when patients are inoperable; ACC/AHA 2020 has no formal pathway for this phenotype. A positive EDGEFIRM result would push atrial SMR into the same guideline-endorsed transcatheter space ventricular SMR occupies today — though surgical MV repair combined with AF ablation carries a Class IIa ESC 2025 recommendation for operable patients, the reference point EDGEFIRM's control arm does not test against. TMVR expands into hostile anatomy: a case-based review lays out ViV, ViR, and ViMAC as three distinct risk profiles — ViV predictable, ViR and ViMAC still marked by embolization and paravalvular leak. A valve-in-ring TMVR case required antegrade LAMPOON, Alfieri-stitch laceration, and VA-ECMO to complete safely. A post-TMVR LVOT obstruction case was rescued with radiofrequency septal ablation — a first-reported bailout. Surgical mitral repair remains Class I in both ACC/AHA 2020 and ESC 2025 when a durable result is expected; these cases define the anatomical frontier where surgery's Class I standing ends and transcatheter rescue begins.
Tricuspid Valve (TriClip, TTVR)
No dedicated tricuspid data today. The ESC 2025 Class IIa endorsement for transcatheter tricuspid intervention in high-risk symptomatic severe TR — based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II — remains the reference point. ACC/AHA 2020 predates all three trials and carries no recommendation for transcatheter tricuspid therapy. Real-world STS/ACC TVT Registry data from EVOQUE (98.4% technical success, 3.1% 30-day mortality) compare favorably against historical isolated TV surgery mortality of 8-20%; contemporary surgical series with earlier referral are closing that gap, and ESC 2025 upgraded TV surgery for symptomatic severe primary TR to Class I on that basis.
Surgical vs. Transcatheter Comparisons
ViV-TAVR is the economically dominant strategy over redo-SAVR for failed bioprostheses in this model. The JSCAI decision-analytic model puts mean total cost at $88,829 for ViV-TAVR versus $91,411 for redo-SAVR, with a 2-month survival edge of 0.97 vs 0.96 and an ICER of -$259,323 per death averted. Cost-effectiveness held in only 57-58% of probabilistic simulations — the authors flag "moderate decisional uncertainty," meaning nearly half the time redo-SAVR wins or ties. Two-month survival is a short horizon; TAV-in-SAV raises patient-prosthesis mismatch risk that manifests years later, and coronary re-access after ViV is a lifetime-management concern ESC 2025 explicitly highlights. The Medicare sequential-intervention analysis reinforces this: 0.86% of TAVR patients, 2.69% of M-TEER, and 4.48% of TMVR patients returned for a second transcatheter valve procedure within 5 years, at median intervals of 229, 300, and 483 days. Index-procedure planning for future access is no longer optional.
Device & Technology
The vascular closure evidence hardens. The hybrid suture-plus-plug meta-analysis shows RR 0.50 for major vascular complications, RR 0.58 for minor, and RR 0.26 for VCD failure with no bleeding penalty. This aligns with the earlier percutaneous cannulation registry favoring plug-based devices for immediate hemostasis. Dual-Perclose as the default transfemoral closure strategy has a harder evidence case to make.
Clinical Trial Updates
EDGEFIRM is the trial to watch: multicenter, open-label, 2:1 randomization of M-TEER + GDMT versus GDMT in HFpEF patients with aFMR grade >II or grade II with hemodynamic relevance, deemed high surgical risk. Primary composite is CV mortality, HF hospitalization, or KCCQ improvement <10 points at one year. A positive result would shift ESC's IIb aFMR recommendation upward and force ACC/AHA to formally define the entity.
Industry & Market
Edwards is framed by sell-side commentary as steady on TAVR-driven margins ahead of its July 23 print. Global Market Insights released its 2035 TAVR forecast, with asymptomatic-AS indication expansion (post-EARLY TAVR) and ESC 2025's age-70 threshold shift as the primary TAM drivers. The demand-side tailwind is real; durability at 15 years remains the analyst blindspot.
Financial Analysis
The market is pricing structural heart divergence. Edwards trades at 24.5x forward earnings with a target implying 22% upside — the market accepting TAVR volume growth but not yet paying for it. Boston Scientific's 53% six-month collapse to $44.25 does not square with a Watchman/structural heart story alone; the July 29 print will clarify whether this is sector rotation or execution failure. Medtronic at 13x forward is priced as a diversified med-tech, not a structural heart pure-play — CoreValve's self-expanding pacemaker penalty in today's meta-analysis is a headwind the multiple already reflects. Anteris (AVR.AX) at +25% over six months is the pre-revenue narrative trade on DurAVR, unmoored from durability data that does not yet exist.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $82.63, down 1.42% on the day, down 1.95% over six months.
- Market cap $47.6B; trailing P/E 49.2, forward P/E 24.5; beta 0.85; 52-week range $72.30-$96.29.
- 25-analyst consensus target $100.48 (range $84-$110); recommendation: buy.
- Earnings reported July 23 (EPS est $0.74, revenue est $1.68B).
The pure-play TAVR name benefits most directly from EARLY TAVR asymptomatic-AS expansion and ESC 2025's age-70 threshold shift. The balloon-expandable pacemaker advantage in today's meta-analysis (RR 1.40 vs 2.57 self-expanding) is a quiet tailwind for SAPIEN volumes over CoreValve in low-risk patients.
Medtronic (MDT)
- Close $83.21, up 1.46% on the day, down 15.92% over six months.
- Market cap $106.5B; trailing P/E 22.3, forward P/E 13.0; beta 0.58; 52-week range $73.31-$106.33.
- 25-analyst target $97.84; recommendation: buy.
- Next earnings September 1 (EPS est $1.39, revenue est $9.55B).
Evolut's platform-specific pacemaker and reintervention signal in today's meta-analysis is a durability-marketing headwind Medtronic will need to counter with its own 5- and 10-year data updates.
Abbott (ABT)
- Close $103.06, up 2.29% on the day, down 3.98% over six months.
- Market cap $179.5B; trailing P/E 33.4, forward P/E 17.0; beta 0.61; 52-week range $81.97-$137.49.
- 24-analyst target $119.12; recommendation: buy.
- Next earnings October 14 (EPS est $1.42, revenue est $12.99B).
MitraClip and TriClip anchor the structural heart franchise. EDGEFIRM's launch — testing M-TEER in aFMR/HFpEF — is Abbott's next indication-expansion catalyst if positive.
Boston Scientific (BSX)
- Close $44.25, up 1.54% on the day, down 52.70% over six months.
- Market cap $65.8B; trailing P/E 18.5, forward P/E 11.9; beta 0.58; 52-week range $42.20-$109.50.
- 28-analyst target $72.43 (range $55-$106); recommendation: strong buy.
- Next earnings July 29 (EPS est $0.83, revenue est $5.37B).
Analyst consensus remains strong buy despite the six-month collapse — the July 29 print will determine whether the reset creates entry or confirms a structural growth deceleration in ACURATE neo2 and Watchman.
Anteris Technologies (AVR.AX)
- Close A$11.50, up 1.14% on the day, up 25.00% over six months.
- Market cap A$1.1B; forward P/E -5.27; beta 0.73; 52-week range A$4.86-A$15.47.
- Single-analyst target A$13.00.
The DurAVR single-piece leaflet story remains a pre-pivotal narrative trade — the six-month gain reflects investor appetite for a differentiated durability pitch, not evidence of it.
Market outlook: Structural heart is bifurcating. Edwards holds the TAVR volume-growth narrative; Boston Scientific must defend the peripheral structural heart thesis on July 29; Medtronic carries a platform-specific overhang that today's meta-analysis reinforces. The sector's growth premium now depends on indication expansion (asymptomatic AS, aFMR, TR) more than on incremental share within severe symptomatic AS.
Next up: Boston Scientific reports Tuesday. EDGEFIRM enrollment kicks off. With ESC 2025's age-70 TAVI threshold now four months old, first-quarter European volume data will show how fast practice actually moves when a guideline shifts.